Since FGFR1 is among the most common mutations in BC patients, a concomitant treatment with the inhibitors of ER, CDK4/6, and FGFR1 could also be a valid first-line treatment alternative to avoiding the emergence of therapy resistance. This evidence concerns the gene ESR1 and breast cancer.